VCYT Q2 2023 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$90M+24.0% YoY

Gross Profit

$56M61.8% margin

Operating Income

-$8M-8.9% margin

Net Income

-$8M-9.3% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+9.6%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$13M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$78M

Stockholders' Equity

$1.1B

Cash & Equivalents

$191M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$90M	$73M	+24.0%
Gross Profit	$56M	$48M	+16.7%
Operating Income	-$8M	-$11M	+25.0%
Net Income	-$8M	-$10M	+11.9%

Revenue Segments

Testing

$82M91%

Biopharmaceutical And Other

$5M5%

Product

$4M4%